Where the Value Sits in Pharma Logistics

Why pharma logistics is becoming harder to ignore

Pharma logistics is drawing increasing attention, but not simply because healthcare is growing.

According to OECD data, healthcare expenditure across developed markets already sits at roughly 9-10% of GDP, and IQVIA expects global medicine use to keep rising toward 2030. What is changing more significantly is the nature of the products moving through the supply chain.

A greater share of pharmaceutical volume now consists of biologics and advanced therapies, increasing requirements around temperature control and regulatory compliance.

As a result, logistics providers are no longer simply transporting goods. They are responsible for maintaining product integrity across tightly controlled conditions, often under time-critical constraints.

This shift is gradually separating pharma logistics from general freight forwarding and reinforcing its position as a specialised, capability-led segment.

This is not one market: it is a stack of specialist niches

Simplified view of the pharma logistics value chain, highlighting key segments:

Pharma logistics is often grouped as a single market, but it spans several distinct segments: from GDP-compliant warehousing and distribution to specialist freight forwarders, and cold-chain or advanced therapy operators. The highest-quality assets are usually not the broadest operators; they are the ones with a narrow capability set that is difficult to replicate.

From an M&A perspective, these segments are not equally attractive.

The strongest businesses tend to be those with defined, hard-to-replicate capabilities, particularly in areas such as temperature-controlled logistics and high-value, time-critical forwarding.

By contrast, more generalist transport or lower-barrier courier models tend to be less differentiated and attract less strategic interest.

Investment activity reflects a focus on capability

Recent transaction activity highlights how strategic buyers are approaching the sector.

• UPS Healthcare acquired Bomi Group to expand its temperature-controlled logistics infrastructure and European footprint

• 
  

• DHL Group in 2025, announced a $2 billion investment in DHL Health Logistics by 2030, and acquired CRYOPDP, strengthening its position in clinical trials and advanced therapies

  
  

• Yusen Logistics acquisition of Walden Group’s healthcare businesses (including Movianto, Eurotranspharma and Transpharma International), building a warehouse-led specialist healthcare end to end platform, integrated across transportation, cold storage and forwarding

  
  

• Investor backing of companies such as Envirotainer reflects continued demand for specialised cold-chain infrastructure

  
  

The pattern is clear: buyers are prioritising highly specialised, hard-to-enter segments that require specific infrastructure and operational capability.

What we are seeing in conversations

In our conversations across the market, a few themes keep repeating.

• Buyers are generally more interested in specialisation than scale. A mid-sized operator with genuine clinical-trial or high-spec cold-chain capability often gets more attention than a larger generalist.

  
  

• Asset-light models are often viewed more favourably than heavy-asset companies, provided they control quality procedures and are embedded with the manufacturers and wholesalers.

  
  

• Businesses that operate as control towers, managing qualified partner networks, are attractive because they scale without the same capital requirement.

  
  

• The market remains fragmented, often regional and privately owned. Most businesses aren't actively pursuing a sale but many are open to building strategic relationships with a view to a future exit. As a result, transaction timelines are often longer.

Where the best opportunities are likely to sit

From an investment perspective, the most attractive areas of the market tend to include:

• Specialist pharma freight forwarding

• Clinical trial logistics providers

• GDP-compliant 3PL and distribution centres

• Cold-chain and advanced therapy logistics specialists

  
  

The less interesting areas, at least from a platform-building perspective, are usually the ones where capability is easier to replicate or differentiation rests mainly on physical capacity rather than know-how: general courier work, conventional road haulage and standalone customs brokerage.

Pharma logistics is becoming more valuable as it becomes more complex. That complexity is exactly what creates defensible value.

The sector is fragmented, still founder-heavy and still uneven in quality, which is exactly why it continues to attract strategic and private equity buyer interest.

Sources

• OECD - Health Expenditure Data

• IQVIA Institute - Global Use of Medicines Outlook

• UPS - Bomi Group acquisition

• DHL Group - Healthcare investment & CRYOPDP acquisition

• Yusen Logistics - Walden Health acquisition